(Q37602847)

21 August 2017

1 reference

title

Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries (English)

1 reference

21 August 2017

main subject

anti-retroviral agent

0 references

author name string

John A Bartlett

series ordinal

1

1 reference

21 August 2017

John F Shao

series ordinal

2

1 reference

21 August 2017

publication date

1 October 2009

1 reference

Lancet Infectious Diseases

21 August 2017

published in

1 reference

21 August 2017

volume

9

1 reference

21 August 2017

issue

10

1 reference

21 August 2017

page(s)

637-649

1 reference

Brazilian policy of universal access to AIDS treatment: sustainability challenges and perspectives

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Utilization of antiretroviral treatment in Ethiopia between February and December 2006: spatial, temporal, and demographic patterns

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Antiretroviral therapy in a thousand patients with AIDS in Haiti

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Scaling up antiretroviral therapy in South Africa: the impact of speed on survival

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Knowledge, attitudes, and practices of antiretroviral therapy among HIV-infected adults attending private and public clinics in India

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Economic Stress and HIV-Associated Health Care Utilization in a Rural Region of China: A Qualitative Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Bridging the gap between antiretroviral access and adherence in Mexico.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Patterns of movement and risk of HIV infection in rural Zimbabwe

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Planning STI/HIV prevention among refugees and mobile populations: situation assessment of Sudanese refugees

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Rural-to-Urban Migrants and the HIV Epidemic in China

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

How many child deaths can we prevent this year?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Evaluating guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Initiation of Antiretroviral Therapy at CD4 Cell Counts ≥350 Cells/mm3 Does Not Increase Incidence or Risk of Peripheral Neuropathy, Anemia, or Renal Insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Hepatotoxicity associated with nevirapine use.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Adherence to antiretroviral therapy in resource-limited settings: everything matters

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Tenofovir renal safety in HIV-infected patients: Results from the SCOLTA Project

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Mortality and virologic outcomes after access to antiretroviral therapy among a cohort of HIV-infected women who received single-dose nevirapine in Lusaka, Zambia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Task shifting for antiretroviral treatment delivery in sub-Saharan Africa: not a panacea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy: evidence from the Italian cohort of antiretroviral-naive patients study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Trends of prevalence of primary HIV drug resistance in Germany

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

HIV drug resistance pattern among HAART-exposed patients with suboptimal virological response in Ouagadougou, Burkina Faso

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

New patterns of HIV-1 resistance during HAART

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970227-0

7 January 2021

10.1016/S1473-3099(09)70227-0

Identifiers

DOI

1 reference

21 August 2017

1 reference